塞德斯醫療 CLDX 深 滬
等待開盤 01-29 09:30:00 美东时间
24.77
-1.460
-5.57%
華盛通- 最 高26.21
- 今 開26.21
- 成交量 35.96万股
- 最 低 24.5813
- 昨 收 26.23
- 總市值 16.46亿
- 52周最高 30.50
- 市盈率 靜 --
- 換手率 0.54%
- 52周最低 14.40
- 委 比 14.19%
- 總股本 6644.95万
- 歷史最高 582.60
- 量 比 0.77
- 振 幅 6.21%
- 歷史最低 1.50
- 每 手 1
- 風險率 3.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Barclays Maintains Underweight on Celldex Therapeutics, Raises Price Target to $24
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Underweight and raises the price target from $21 to $24.
2025-12-18 01:38
Celldex Initiates Global Phase 3 Trial To Establish Efficacy And Safety Of Barzolvolimab In Adult Patients With ColdU And SD Who Remain Symptomatic Despite H1 Antihistamine Treatment
No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient lifeBarzolvolimab is the only drug in development to demonstrate clinical benefit in patients in
2025-12-09 21:10
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
Barclays Maintains Underweight on Celldex Therapeutics, Lowers Price Target to $21
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Underweight and lowers the price target from $25 to $21.
2025-11-11 23:03
Celldex Therapeutics Q3 EPS $(1.01) Misses $(0.91) Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.91) by 10.87 percent. This is a 57.81 percent decrease over losses of $(0.64) per share
2025-11-11 05:46
Celldex to Present at Upcoming Investor Conferences
Celldex announced that its management will participate in fireside chats at three upcoming investor conferences: the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11 at 10:00 am ET, the TD Cowen Immunology & Inflammation Summit on November 13 at 9:30 am ET, and the 8th Annual Evercore Healthcare Conference on December 2 at 3:00 pm ET. Live webcasts and 90-day replays will be available on the Events & Presentations page of Cel...
2025-11-07 13:01
Celldex Releases Phase 1 Results For Its Bispecific Antibody CDX-622 Showing Drug Was Well Tolerated, Showed Favorable Pharmacokinetics, And Led To Rapid, Sustained Reductions In Serum Tryptase, Confirming Effective Mast Cell Inhibition
Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and
2025-10-31 04:14
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
2025-10-22 10:10
Mizuho Initiates Coverage On Celldex Therapeutics with Outperform Rating, Announces Price Target of $48
Mizuho analyst Joseph Catanzaro initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Outperform rating and announces Price Target of $48.
2025-10-21 20:44
